Sotorasib for Lung Cancers with KRAS p.G12C Mutation.

Ferdinandos Skoulidis,Bob T. Li,Grace K. Dy,Timothy J. Price,Gerald Steven Falchook,Jürgen Wolf,Antoine Italiano,Martin Schuler,Hossein Borghaei,Fabrice Barlesi,Terufumi Kato,Alessandra Curioni Fontecedro,Adrian G. Sacher,Alexander I. Spira,Suresh S. Ramalingam,Toshiaki Takahashi,Benjamin Besse,Abraham Anderson,Agnes Ang,Qui Tran,Omar Mather,Haby Henary,Gataree Ngarmchamnanrith,Gregory Friberg,Vamsidhar Velcheti,Ramaswamy Govindan

Sotorasib for Lung Cancers with KRAS p.G12C Mutation.

2021

Abstract Background Sotorasib showed anticancer activity in patients with KRAS p.G12C–mutated advanced solid tumors in a phase 1 study, and particularly promising anticancer activity was observed i...

Keywords:

in patient
Medicine
Extramural
Cancer research
multicenter study
Lung
Progression-free survival
Carcinoma
Mutation
KRAS

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations